great post andres, excellent insight shown . The Board has in the interest of shareholders reviewed the strategy and made a decision not to raise capital in this market and to proceed with a compliance listing at a time of their choosing . The Board has yet again illustrated excellent judgment and commercial astuteness by implementing the new strategy given the negative sentiment on the nasdaq and the fact they do not need to raise funds . .
The company can now focus on the results without having the pressure on the SP that would potentially have been caused by casual investors in the US and also those on the ASX that are not invested for the fundamentals but that would be seeking to exit for a stag on listing , particularly given the current negative climate for biotechs in the US.
Once favourable results are announced on OSA or other trials in the pipeline ,the company will be in an excellent position and be significantly re -rated as you suggest . The company can then proceed with any CR if needed from a position of strength on their own timing and terms and may well indeed as you say attract suitors for a trade sale if that is the path they choose to proceed down . Excellent work by the Board . We await the results . Exciting times ahead .
IHL Price at posting:
57.0¢ Sentiment: Buy Disclosure: Held
